|
Report No. : |
336633 |
|
Report Date : |
25.08.2015 |
IDENTIFICATION DETAILS
|
Name : |
AL ANDALOUS PHARMACEUTICAL INDUSTRIES |
|
|
|
|
Registered Office : |
El Zeny Tower, 6th Floor, 25 Misr Helwan Agricultural Road,
Maadi, Cairo |
|
|
|
|
Country : |
Egypt |
|
|
|
|
Year of Establishment : |
2011 |
|
|
|
|
Com. Reg. No.: |
14374 |
|
|
|
|
Legal Form : |
Egyptian Joint
Stock Company |
|
|
|
|
Line of Business : |
Subject is engaged in the manufacture of pharmaceuticals and cosmetics. Subject's product range includes : Alimentry tract and metabolism , Blood and blood, forming organs, Cardiovascular System, Dermatologicals, Genito - Urinary system and sex hormones, Systemi hormonal preparations (excluding sex hormones), General Anti-infectives, Systemic, Antineoplastic and immunodulating agents, Musculo- skeletal system, Central Nervous System, Food supplements, Cosmetics. |
|
|
|
|
No. of Employee : |
70 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
No complaints |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made on
e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31, 2015
|
Country Name |
Previous Rating (31.12.2014) |
Current Rating (31.03.2015) |
|
Egypt |
B2 |
B2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
EGYPT - ECONOMIC OVERVIEW
Occupying the northeast corner of the African continent, Egypt is bisected by the highly fertile Nile valley, where most economic activity takes place. Egypt's economy was highly centralized during the rule of former President Gamal Abdel NASSER but opened up considerably under former Presidents Anwar EL-SADAT and Mohamed Hosni MUBARAK. Cairo from 2004 to 2008 pursued business climate reforms to attract foreign investment and facilitate growth. Poor living conditions and limited job opportunities for the average Egyptian contribute to public discontent, a major factor leading to the January 2011 revolution that ousted Mubarak. The uncertain political, security, and policy environment since 2011 caused economic growth to slow significantly, hurting tourism, manufacturing, and other sectors and pushing up unemployment. Weak growth and limited foreign exchange earnings have made public finances unsustainable, leaving authorities dependent on expensive borrowing for deficit finance and on Gulf allies to help cover the import bill. Egypt's current Constitution passed in a referendum that took place in January 2014.
|
Source
: CIA |
Company Name :
AL ANDALOUS PHARMACEUTICAL INDUSTRIES
Country of Origin :
Egypt
Legal Form :
Egyptian Joint Stock Company
Registration Date :
2011
Commercial Registration Number :
14374
Tax Card Number :
613-541-685
Issued Capital :
£E 2,000,000
Paid up Capital :
£E 2,000,000
Total Workforce : 70
Activities :
Manufacturers of pharmaceuticals and cosmetics
Financial Condition :
Fair
Payments :
Nothing detrimental uncovered
AL ANDALOUS
PHARMACEUTICAL INDUSTRIES
Building : El Zeny
Tower, 6th Floor
Street : 25 Misr
Helwan Agricultural Road
Area : Maadi
Town : Cairo
Country : Egypt
Telephone : (20-2) 23580826
/ 23580832 / 23580752
Facsimile : (20-2)
23580507
Email : nhany@alandalous.org / info@alandalous.org
Subject operates from a medium sized suite of offices that are rented
and located in the Central Business Area of Cairo.
Branch Office (s)
Location Description
· Section 6/7 - 6th
Industrial Zone Factory
premises covering 14,000
6th of
October City square
metres
Tel: (20-2) 38290359 / 38290357 / 8 / 9
Fax: (20-2)
38290358 / 38290441
· Alexandria Office
premises
· El Mansoura Office
premises
· Assiut Office
premises
Name Position
· Mohamed Ahmed
Ibrahim Managing
Director
· Safwat Abd El
Moneim Factory
Manager
· Hazem Mahmoud Financial
Manager
· Mohamed Abbass Administration
Manager
Date of
Establishment : 2011
Legal Form : Egyptian Joint
Stock Company
Commercial Reg.
No. : 14374
Tax Card No. : 613-541-685
Issued Capital : £E 2,000,000
Paid up Capital : £E 2,000,000
· Mohamed Ahmed Ibrahim 97%
· Menah Mohamed
Ahmed Ibrahim 1%
· Moustafa Mohamed
Ahmed Ibrahim 1%
· Noha Zaazouaa 1%
· Al Andalous
Medical Company
El Zeny Tower, 6th Floor
25 Misr Helwan Agricultural Road
Maadi
Cairo
Tel: (20-2) 23580826 / 23580832 / 23580752
Fax: (20-2) 23580507
Activities: Engaged in the manufacture of pharmaceuticals and cosmetics. Subject's
product range includes:
Alimentry tract and metabolism
Blood and blood forming organs
Cardiovascular System
Genito - Urinary system and sex hormones
Systemi hormonal preparations (excluding sex hormones)
General Anti-infectives , Systemic
Antineoplastic and immunodulating
agents
Musculo- skeletal system
Central Nervous System
Food supplements
Cosmetics
Import Countries: Europe and the Far East
Subject has a workforce of 70 employees.
Financial highlights provided by local sources are given below:
Currency: Egyptian Pounds (£E)
Year
Ending 31/12/13: Year Ending
31/12/14:
Total Sales £E
11,250,000 £E
11,615,000
Local sources consider subject’s financial condition to be Fair.
The above financial figures are based on estimations by our local
sources.
·
Commercial International Bank (CIB)
Nile Tower Building
21-23 Giza Street
PO Box: 2430
Cairo
Tel: (20-2) 25703043
Fax: (20-2) 25703172 / 25072691
No complaints regarding subject’s payments have been reported.
According to local sources, subject meets its payment obligations in a
timely manner and the company is considered to be a fair trade risk.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.66.51 |
|
|
1 |
Rs.104.01 |
|
Euro |
1 |
Rs.76.27 |
INFORMATION DETAILS
|
Analysis Done by
: |
RAS |
|
|
|
|
Report Prepared
by : |
ASH |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s
credit risk and to set the amount of credit to be extended. It is calculated
from a composite of weighted scores obtained from each of the major sections of
this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.